Millennium Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-84,085
Closed -$1.81M 5701
2025
Q4
$1.81M Sell
84,085
-8,315
-9% -$161K ﹤0.01% 4028
2025
Q3
$1.41M Buy
92,400
+74,400
+413% +$968K ﹤0.01% 4350
2025
Q2
$159K Sell
18,000
-77,378
-81% -$680K ﹤0.01% 5434
2025
Q1
$747K Sell
95,378
-1,116,626
-92% -$9.35M ﹤0.01% 4568
2024
Q4
$12.7M Buy
1,212,004
+233,986
+24% +$2.84M 0.01% 1944
2024
Q3
$12.8M Buy
978,018
+964,257
+7,007% +$14.7M 0.01% 1969
2024
Q2
$193K Sell
13,761
-1,798,556
-99% -$29.3M ﹤0.01% 5150
2024
Q1
$30.6M Buy
1,812,317
+1,607,783
+786% +$23.9M 0.01% 1178
2023
Q4
$2.89M Buy
204,534
+149,808
+274% +$1.76M ﹤0.01% 3289
2023
Q3
$564K Buy
+54,726
New +$733K ﹤0.01% 4587
2023
Q2
Sell
-288,910
Closed -$2.65M 6099
2023
Q1
$2.65M Sell
288,910
-320,426
-53% -$2.63M ﹤0.01% 3162
2022
Q4
$4.36M Buy
+609,336
New +$4.27M ﹤0.01% 2931
2022
Q3
Sell
-212,590
Closed -$519K 7049
2022
Q2
$519K Buy
+212,590
New +$873K ﹤0.01% 4920
2022
Q1
Sell
-22,733
Closed -$156K 6887
2021
Q4
$184K Buy
+22,733
New +$208K ﹤0.01% 5968
2021
Q2
Sell
-32,378
Closed -$293K 6509
2021
Q1
$293K Sell
32,378
-282,973
-90% -$2.29M ﹤0.01% 5228
2020
Q4
$2.11M Sell
315,351
-265,775
-46% -$1.66M ﹤0.01% 3195
2020
Q3
$2.93K Buy
581,126
+154,245
+36% +$1.12M ﹤0.01% 2300
2020
Q2
$3.45M Sell
426,881
-28,015
-6% -$247K ﹤0.01% 2100
2020
Q1
$3.61M Sell
454,896
-173,931
-28% -$1.34M 0.01% 1590
2019
Q4
$4.75M Buy
628,827
+509,939
+429% +$2.69M 0.01% 1981
2019
Q3
$494K Buy
+118,888
New +$298K ﹤0.01% 3262
2019
Q2
Sell
-64,728
Closed -$93K 4038
2019
Q1
$93K Sell
64,728
-8,393
-11% -$19K ﹤0.01% 3852
2018
Q4
$189K Buy
+73,121
New +$249K ﹤0.01% 3409
2018
Q3
Sell
-331,554
Closed -$2.03M 3875
2018
Q2
$2.03M Sell
331,554
-375,225
-53% -$2.63M ﹤0.01% 2388
2018
Q1
$5.15M Sell
706,779
-137,621
-16% -$1.21M 0.01% 1793
2017
Q4
$6.92M Buy
844,400
+178,200
+27% +$1.67M 0.01% 1562
2017
Q3
$7M Sell
666,200
-100,173
-13% -$956K 0.01% 1474
2017
Q2
$8.45M Buy
766,373
+618,954
+420% +$6.21M 0.02% 1149
2017
Q1
$1.43M Buy
+147,419
New +$1.47M ﹤0.01% 2193
2016
Q4
Sell
-163,884
Closed -$2.03M 3315
2016
Q3
$2.03M Sell
163,884
-446,488
-73% -$5.83M ﹤0.01% 1928
2016
Q2
$6.55M Buy
610,372
+141,201
+30% +$1.51M 0.02% 1095
2016
Q1
$5.18M Buy
469,171
+214,923
+85% +$2.13M 0.01% 1235
2015
Q4
$3.1M Buy
254,248
+107,470
+73% +$1.68M 0.01% 1657
2015
Q3
$2.39M Buy
146,778
+108,460
+283% +$2.39M ﹤0.01% 1786
2015
Q2
$812K Sell
38,318
-1,793,542
-98% -$32.2M ﹤0.01% 2381
2015
Q1
$32.9M Buy
1,831,860
+736,721
+67% +$11.5M 0.06% 413
2014
Q4
$18.8M Buy
1,095,139
+460,922
+73% +$6.58M 0.04% 639
2014
Q3
$9.08M Sell
634,217
-153,618
-19% -$2.21M 0.02% 920
2014
Q2
$11.8M Sell
787,835
-473,843
-38% -$5.72M 0.03% 741
2014
Q1
$16.9M Buy
1,261,678
+1,080,910
+598% +$11.6M 0.05% 523
2013
Q4
$1.46M Sell
180,768
-82,947
-31% -$585K ﹤0.01% 2050
2013
Q3
$1.73M Buy
263,715
+203,225
+336% +$1.25M 0.01% 1781
2013
Q2
$371K Buy
+60,490
New +$312K ﹤0.01% 2478

Other funds holding AVDL

Millennium Management's AVDL Position: Q1 2026 in Review

Millennium Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 84,085 shares — an estimated $1.81M sold.

Millennium Management first reported a position in AVDL in Q2 2013 and held it in 43 quarters. The position peaked at $32.9M in Q1 2015. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Millennium Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 84,085 Avadel Pharmaceuticals shares in Q1 2026, an estimated $1.81M.
  • Millennium Management first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 43 quarters.
  • Millennium Management's Avadel Pharmaceuticals position peaked at $32.9M in Q1 2015.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.